Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Authors
Keywords
-
Journal
PHARMACOLOGICAL RESEARCH
Volume 183, Issue -, Pages 106362
Publisher
Elsevier BV
Online
2022-07-22
DOI
10.1016/j.phrs.2022.106362
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib for the treatment of active ankylosing spondylitis in adults
- (2022) Raagav Mohanakrishnan et al. Expert Review of Clinical Immunology
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- (2022) Mikhail M. Kostik et al. Frontiers in Pediatrics
- The suitability of treating atopic dermatitis with Janus kinase inhibitors
- (2022) Shanthi Narla et al. Expert Review of Clinical Immunology
- Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
- (2022) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation
- (2022) Caleb R. Glassman et al. SCIENCE
- JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
- (2022) Bilal Rah et al. Frontiers in Pharmacology
- A Comprehensive Overview of Globally Approved JAK Inhibitors
- (2022) Ahmed M. Shawky et al. Pharmaceutics
- Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
- (2022) Maria Napolitano et al. Drug Design Development and Therapy
- The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
- (2022) Peter J. Richardson et al. Vaccines
- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof
- (2021) Ryan R. Davis et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
- (2021) Wenli Yang et al. Drug Design Development and Therapy
- PERK Pathway and Neurodegenerative Disease: To Inhibit or to Activate?
- (2021) Talya Shacham et al. Biomolecules
- Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies
- (2021) Paul D. Leeson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Kinase drug discovery 20 years after imatinib: progress and future directions
- (2021) Philip Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
- (2021) Yunchao Chang et al. BLOOD
- Upadacitinib Pharmacokinetics and Exposure‐Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients – Analyses of Phase 3 Clinical Trials
- (2021) Elena Muensterman et al. CTS-Clinical and Translational Science
- GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
- (2021) Stefania Demuro et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Trends in kinase drug discovery: targets, indications and inhibitor design
- (2021) Misty M. Attwood et al. NATURE REVIEWS DRUG DISCOVERY
- Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Abrocitinib: First Approval
- (2021) Emma D. Deeks et al. DRUGS
- Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
- (2021) Cecilia C. Ayala-Aguilera et al. JOURNAL OF MEDICINAL CHEMISTRY
- Kincore: a web resource for structural classification of protein kinases and their inhibitors
- (2021) Vivek Modi et al. NUCLEIC ACIDS RESEARCH
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
- (2021) Robert Roskoski Jr. PHARMACOLOGICAL RESEARCH
- The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias
- (2020) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
- (2020) Adriana Coricello et al. MOLECULES
- Targeting ERK1/2 protein-serine/threonine kinases in human cancers
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Fedratinib: First Approval
- (2019) Hannah A. Blair DRUGS
- Upadacitinib: First Approval
- (2019) Sean Duggan et al. DRUGS
- The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The regulation of JAKs in cytokine signaling and its breakdown in disease
- (2018) Henrik M. Hammarén et al. CYTOKINE
- Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
- (2018) Michael L. Vazquez et al. JOURNAL OF MEDICINAL CHEMISTRY
- PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
- (2018) Fabrice Carles et al. MOLECULES
- Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
- (2018) Robert Roskoski et al. PHARMACOLOGICAL RESEARCH
- The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The Jakinibs in systemic lupus erythematosus: progress and prospects
- (2018) Chi Chiu Mok EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Guidelines for preparing color figures for everyone including the colorblind
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Molecular inflation, attrition and the rule of five
- (2016) Paul D. Leeson ADVANCED DRUG DELIVERY REVIEWS
- Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
- (2016) Martin K. Bayliss et al. DRUG DISCOVERY TODAY
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
- (2015) L. Springuel et al. HAEMATOLOGICA
- AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
- (2015) Samuel H. Myers et al. JOURNAL OF MEDICINAL CHEMISTRY
- Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
- (2015) Sean Ekins et al. PHARMACEUTICAL RESEARCH
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
- (2015) L. Springuel et al. HAEMATOLOGICA
- The molecular regulation of Janus kinase (JAK) activation
- (2014) Jeffrey J. Babon et al. BIOCHEMICAL JOURNAL
- Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery
- (2014) Timothy J. Ritchie et al. JOURNAL OF MEDICINAL CHEMISTRY
- The role of ligand efficiency metrics in drug discovery
- (2014) Andrew L. Hopkins et al. NATURE REVIEWS DRUG DISCOVERY
- ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
- (2014) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition
- (2014) P. J. Lupardus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
- (2013) Robert Roskoski Expert Opinion on Drug Discovery
- KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
- (2013) Oscar P. J. van Linden et al. JOURNAL OF MEDICINAL CHEMISTRY
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
- (2013) Hiruy S. Meharena et al. PLOS BIOLOGY
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
- (2012) Vandana Lamba et al. CURRENT PHARMACEUTICAL DESIGN
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Evolution of the eukaryotic protein kinases as dynamic molecular switches
- (2012) S. S. Taylor et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Approaches to discover non-ATP site kinase inhibitors
- (2012) Lori Krim Gavrin et al. MedChemComm
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- MEK1/2 dual-specificity protein kinases: Structure and regulation
- (2011) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
- (2010) Jill E. Chrencik et al. JOURNAL OF MOLECULAR BIOLOGY
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
- (2009) David M. Goldstein et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
- (2009) Neal K. Williams et al. JOURNAL OF MOLECULAR BIOLOGY
- A helix scaffold for the assembly of active protein kinases
- (2008) A. P. Kornev et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The JAK kinases: Not just another kinase drug discovery target
- (2008) Andrew F. Wilks SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation